Kancera strengthens its patent portfolio in cancer metabolism

Kancera report that the Company has registered a patent application for novel compounds targeting the energy metabolism of cancer. The new patent application covers a strategy to facilitate the uptake of substances in cancer cells. These synthetic molecules weaken...

Read More

iNovacia, GE Healthcare and scientists at Karolinska Institutet collaborate to advance drug discovery strategies

In an ongoing and open collaboration between iNovacia AB, GE Healthcare, Sweden and scientists at the Department of Medical Biochemistry and Biophysics (MBB) at Karolinska Institutet, the surface plasmon resonance and nuclear magnetic resonance techniques have been cross-validated as...

Read More

Further clinical support for ROR1 as a diagnostic tool and therapeutic target

Kancera co-founder and scientific adviser Professor Håkan Mellstedt has demonstrated a sustained presence of Kancera's ROR1 target over time in patients with non-progressive disease and also a significant increase of this putative tumor target in patients with progressive stages...

Read More

Notice of Extraordinary General Meeting Kancera AB

Aktieägarna i Kancera AB (publ) kallas härmed till extra bolagsstämma torsdagen den 10 november 2011 kl. 16.00 på Kilpatrick Townsend Advokatbyrås kontor, Hovslagargatan 5B, 5 tr i Stockholm.

Read More

iNovacia AB has developed active compounds as a step towards  treatment of a serious parasitic disease

iNovacia, an internationally established contract research company owned by Kancera AB (Nasdaq OMX Stockholm First North, KAN), announces today that highly potent inhibitors of a target protein in the parasite Schistosoma have been developed. This parasite infects annually...

Read More

Kancera has filed patent for new active substances against cancer

Kancera reports that the company has registered an international patent application (PCT/EP2011/066250) for a new class of compounds targeting the energy metabolism of cancer cells. This new class of synthetic molecules inhibits the target protein PFKFB3. Inhibition of this...

Read More

Breakthrough for the Kancera ROR Technology Against Incurable Cancer

Kancera has in collaboration with scientists at the Karolinska Institute identified active compounds that effectively kill pancreatic cancer cells. Annually over 100 000 people are diagnosed with pancreatic cancer in Europe and the US. Ratio of survival, five years...

Read More

Kancera’s ROR Technology to Attack Solid Tumors

At a cancer seminar in Båstad tomorrow, July 7, Professor Håkan Mellstedt will present the basis for further development of Kancera's ROR technology for the purpose of attacking solid tumors that are hard to treat. Kancera has already reported...

Read More

iNovacia Further Develops its Compound Collection

iNovacia, the drug discovery service provider and subsidiary of Kancera AB (Nasdaq OMX Stockholm First North, KAN), today announced the addition of over 20,000 novel compounds to its small-molecule screening collection. This is in line with the continuous development...

Read More

The Annual General Meeting of Kancera AB

The Annual General Meeting of Kancera AB was held in Stockholm on 26 May, 2011. Annual Report and discharge from liabilityThe Company’s Income Statement and Balance Sheet were adopted and the Board of Directors and the Chief Executive Officer...

Read More